Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5

Abstract

Proper regulation of Wnt signaling is critical for normal bone development and homeostasis. Mutations in several Wnt signaling components, which increase the activity of the pathway in the skeleton, cause high bone mass in human subjects and mouse models. Increased bone mass is often accompanied by severe headaches from increased intracranial pressure, which can lead to fatality and loss of vision or hearing due to the entrapment of cranial nerves. In addition, progressive forehead bossing and mandibular overgrowth occur in almost all subjects. Treatments that would provide symptomatic relief in these subjects are limited. Porcupine-mediated palmitoylation is necessary for Wnt secretion and binding to the frizzled receptor. Chemical inhibition of porcupine is a highly selective method of Wnt signaling inhibition. We treated three different mouse models of high bone mass caused by aberrant Wnt signaling, including homozygosity for loss-of-function in Sost, which models sclerosteosis, and two strains of mice carrying different point mutations in Lrp5 (equivalent to human G171V and A214V), at 3 months of age with porcupine inhibitors for 5–6 weeks. Treatment significantly reduced both trabecular and cortical bone mass in all three models. This demonstrates that porcupine inhibition is potentially therapeutic for symptomatic relief in subjects who suffer from these disorders and further establishes that the continued production of Wnts is necessary for sustaining high bone mass in these models.

References

[1] Williams BO. LRP5: from bedside to bench to bone. Bone, 2017, 102: 26-30

[2] Gong Y et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell, 2001, 107: 513-523

[3] Little RD et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet., 2002, 70: 11-19

[4] Boyden LM et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med., 2002, 346: 1513-1521

[5] Burgers TA, Williams BO. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone, 2013, 54: 244-249

[6] Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10: 537-543

[7] Staehling-Hampton K et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet., 2002, 110: 144-152

[8] Balemans W et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet., 2002, 39: 91-97

[9] Cheng C, Wentworth K, Shoback DM. New frontiers in osteoporosis therapy. Annu. Rev. Med., 2020, 71: 277-288

[10] Amgen and UCB announce increased cardiovascular risk in patients receiving romosozumab, an anti-sclerotin antibody. Rheumatology 56, e21 (2017). https://pubmed.ncbi.nlm.nih.gov/28854619/.

[11] Wengenroth M et al. Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology, 2009, 253: 272-276

[12] de Andrade EM et al. Management of trigeminal neuralgia in sclerosteosis. Surg. Neurol. Int., 2013, 4: S455-S459

[13] Tholpady S et al. Cranial reconstruction for treatment of intracranial hypertension from sclerosteosis: case-based update. World Neurosurg., 2014, 81: 442.e1-5

[14] Stein SA et al. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology, 1983, 33: 267-277

[15] Beighton P et al. Sclerosteosis—an autosomal recessive disorder. Clin. Genet., 1977, 11: 1-7

[16] Joiner DM et al. LRP5 and LRP6 in development and disease. Trends Endocrinol. Metab., 2013, 24: 31-39

[17] Zhong ZA et al. Regulation of Wnt receptor activity: implications for therapeutic development in colon cancer. J. Biol. Chem., 2021, 296: 100782

[18] Li X et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem., 2005, 280: 19883-19887

[19] Ellies DL et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res., 2006, 21: 1738-1749

[20] Williams BO. Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J. Bone Miner. Res., 2014, 29: 24-28

[21] Ke J, Xu HE, Williams BO. Lipid modification in Wnt structure and function. Curr. Opin. Lipidol., 2013, 24: 129-133

[22] Liu J et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA, 2013, 110: 20224-20229

[23] Jiang X et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA, 2013, 110: 12649-12654

[24] Proffitt KD et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res., 2013, 73: 502-507

[25] Kahlert UD et al. Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. J. Neuropathol. Exp. Neurol., 2015, 74: 889-900

[26] Guimaraes PPG et al. Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. J. Control Release, 2018, 290: 75-87

[27] Madan B et al. Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Res., 2018, 6: 17

[28] Mirabelli, C. K. et al. Perspectives on the role of Wnt biology in cancer. Sci. Signal. 12, eaay4494 (2019).

[29] Zhang LS, Lum L. Chemical modulation of WNT signaling in cancer. Prog. Mol. Biol. Transl. Sci., 2018, 153: 245-269

[30] Funck-Brentano T et al. Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice. J. Endocrinol., 2018, 238: 13-23

[31] Shah K, Panchal S, Patel B. Porcupine inhibitors: novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway. Pharmacol. Res., 2021, 167: 105532

[32] Niziolek PJ, Warman ML, Robling AG. Mechanotransduction in bone tissue: the A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner. Bone, 2012, 51: 459-465

[33] Cui Y et al. Lrp5 functions in bone to regulate bone mass. Nat. Med., 2011, 17: 684-691

[34] Kramer I et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res., 2010, 25: 178-189

[35] Cheng D et al. Discovery of pyridinyl acetamide derivatives as potent, selective, and orally bioavailable porcupine inhibitors. ACS Med. Chem. Lett., 2016, 7: 676-680

[36] Ai M et al. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell Biol., 2005, 25: 4946-4955

[37] Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem., 2006, 281: 38276-38284

[38] Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet., 2001, 68: 577-589

[39] Loots GG et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res., 2005, 15: 928-935

[40] Cosman F et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med., 2016, 375: 1532-1543

[41] Saag KG et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med., 2017, 377: 1417-1427

[42] Vestergaard Kvist, A. et al. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J. Clin. Med. 10, 1660 (2021).

[43] Whyte MP et al. New explanation for autosomal dominant high bone mass: mutation of low-density lipoprotein receptor-related protein 6. Bone, 2019, 127: 228-243

[44] Brance ML et al. High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6). Bone, 2020, 141: 115550

[45] Takada R et al. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev. Cell, 2006, 11: 791-801

[46] Langton PF, Kakugawa S, Vincent JP. Making, exporting, and modulating Wnts. Trends Cell Biol., 2016, 26: 756-765

[47] Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene, 2017, 36: 1461-1473

[48] Morris A et al. Drug discovery efforts toward inhibitors of canonical Wnt/beta-catenin signaling pathway in the treatment of cancer: a composition-of-matter review (2010-2020). Drug Discov. Today, 2022, 27: 1115-1127

[49] Davis SL et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest. New Drugs, 2020, 38: 821-830

[50] Zhong Z et al. Wntless functions in mature osteoblasts to regulate bone mass. Proc. Natl. Acad. Sci. USA, 2012, 109: E2197-E2204

[51] Zhong ZA et al. Wntless spatially regulates bone development through beta-catenin-dependent and independent mechanisms. Dev. Dyn., 2015, 244: 1347-1355

[52] Maruyama T, Jiang M, Hsu W. Gpr177, a novel locus for bone mineral density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal development. J. Bone Miner. Res., 2013, 28: 1150-1159

[53] Holmen SL et al. Essential role of beta-catenin in postnatal bone acquisition. J. Biol. Chem., 2005, 22: 21162-21168

[54] Glass DA 2nd et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell, 2005, 8: 751-764

[55] Madan S et al. A non-mosaic PORCN mutation in a male with severe congenital anomalies overlapping focal dermal hypoplasia. Mol. Genet. Metab. Rep., 2017, 12: 57-61

[56] Bostwick B et al. Phenotypic and molecular characterization of focal dermal hypoplasia in 18 individuals. Am. J. Med. Genet. C Semin. Med. Genet., 2016, 172C: 9-20

[57] Dreyer T et al. Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis. J. Orthop. Translat., 2021, 29: 134-142

[58] O’Brien, S., Chidiac, R. & Angers, S. Modulation of Wnt-beta-catenin signaling with antibodies: therapeutic opportunities and challenges. Trends Pharmacol. Sci. 44, 354–365 (2023).

[59] Zhang LS, Lum L. Delivery of the porcupine inhibitor WNT974 in mice. Methods Mol. Biol., 2016, 1481: 111-117

[60] Foxa GE et al. Generation and characterization of mouse models for skeletal disease. Methods Mol. Biol., 2021, 2221: 165-191